Vol 13, No 5 (2017)
Review paper
Published online: 2017-11-15
Atezolizumab — PD-L1 inhibitor in non-small-cell lung cancer
DOI: 10.5603/OCP.2017.0029
Oncol Clin Pract 2017;13(5):211-215.
Abstract
Advanced non-small-cell lung cancer is still a challenging disease. Chemotherapy and EGFR or ALK tyrosine
kinase inhibitors are well-established options. Immunotherapy with immune-checkpoint inhibitors significantly
improves survival both in first- and second-line treatment. Atezolizumab is one of the novel immunotherapies. This
paper presents current data on mechanisms of action and clinical data of atezolizumab in second-line treatment
of patients with advanced non-small-cell lung cancer.
Keywords: non-small-cell lung canceradvanced diseaseimmunotherapyatezolizumab
References
- Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017; 6(2): 196–211.
- Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015: 76–83.
- Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996; 8(5): 765–772.
- Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 2013; 73(8): 2381–2388.
- Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004; 10(15): 5094–5100.
- Fehrenbacher L, Spira A, Ballinger M, et al. POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387(10030): 1837–1846.
- McLaughlin J, Han G, Schalper K, et al. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer. JAMA Oncology. 2016; 2(1): 46.
- Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015; 14(4): 847–856.
- Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015; 520(7547): 373–377.
- Sheng J, Fang W, Yu J, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016; 6: 20090.
- Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017; 12(2): 208–222.
- Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230): 124–128.
- Garon E, Rizvi N, Hui R, et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2015; 372(21): 2018–2028.
- Rittmeyer A, Barlesi F, Waterkamp D, et al. OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389(10066): 255–265.
- Krzakowski M. Nowotwory płuca, opłucnej, śródpiersia. In: Krzakowski M, Potemski P, Warzocha K, Wysocki P. ed. Onkologia kliniczna tom II. Via Medica, Gdańsk 2015: 556–558.
- Kawecki M. Current literature review. Oncol Clin Pract. 2016; 12: 197–200.